Ocriplasmin for treating vitreomacular traction

  • Technology appraisal guidance
  • TA297
  • Published: 

We have withdrawn this guidance. Inceptua has stopped marketing Ocriplasmin (Jetrea) and its marketing authorisation has been withdrawn.